CADTH Canadian Drug Expert Committee recommendation. Lixisenatide (Adlyxine -- Sanofi-Aventis Canada inc.) : indication : diabetes mellitus, type 2.

CADTH Canadian Drug Expert Committee recommendation. indication : diabetes mellitus, type 2. Lixisenatide (Adlyxine -- Sanofi-Aventis Canada inc.) :

The CADTH Canadian Drug Expert Committee (CDEC) recommends that lixisenatide be reimbursed for use as an adjunct to diet and exercise to improve glycemic control in adult patients with type 2 diabetes mellitus.

Saved in:

Bibliographic Details
Online Access:	http://www.ncbi.nlm.nih.gov/books/NBK534071/ Full text
Corporate Author:	CADTH Canadian Drug Expert Committee (Author)
Format:	Electronic eBook
Language:	English
Published:	Ottawa (ON) : Canadian Agency for Drugs and Technologies in Health, 2017
Edition:	Version 1.0.
Series:	Common drug review clinical review report.
Subjects:	Diabetes Mellitus, Type 2 > drug therapy. Hypoglycemic Agents > therapeutic use. Peptides > therapeutic use. Hypoglycemic Agents > economics. Cost-Benefit Analysis. Insurance, Health, Reimbursement. Canada.

Clinical review report. Lixisenatide (Adlyxine) (Sanofi-aventis Canada Inc.)

Version: 1.0.

Published 2017

Get full text
Full text

Electronic eBook

Pharmacoeconomic review report. Lixisenatide (Adlyxine) (Sanofi-aventis Canada Inc.).